Also known as: TA1
Molecular Weight
3108 Da
Half-Life
2 hours
Evidence Passport
Evidence strength, status, identity, route and safety are scored separately.
Human evidence
Confirmatory human evidence
Phase 3 evidence is recorded, but the exact indication and study population still matter.
Development status
Phase 3 development or evidence
Investigational development is not the same as approval or product suitability.
Identity match
Named compound linked
Sources are linked to the named compound; formulation and product quality remain separate questions.
Route relevance
Route match not verified
Catalogue route: Subcutaneous injection. A matching human study route is not confirmed.
Safety record
5 documented flags
Documented flags are visible, but absence of a listed risk would not prove safety.
3 app-verified sources linked · Version 2026-08-31
A 28-amino acid immunomodulating polypeptide that stimulates both innate and adaptive immune responses. Activates Toll-like receptors and downstream signaling pathways. Restores immune homeostasis and enhances T-cell function, dendritic cell maturation, and cytokine production.
These topics describe the catalogue's research index. They are not promised outcomes or personal recommendations.
Contraindications:
Thymosin alpha-1 in hepatitis B treatment (2008)
Demonstrated antiviral efficacy in chronic hepatitis B patients
DOI: 10.1016/j.jhep.2008.03.023Explore more peptides in this category
View All Immune Peptides →Research Disclaimer: This information is compiled from published research and is provided for educational purposes only. Peptides discussed here are classified as research chemicals in most jurisdictions and are not FDA-approved for human use unless otherwise noted. Consult a qualified healthcare provider before starting any protocol.